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Abstract
Background: Existing cut-offs for fasting plasma glucose (FPG) and post-load glucose (2hPG)
criteria are not equivalent in the diagnosis of diabetes and glucose intolerance. Adjusting cut-offs
of single measurements have not helped so we undertook this project to see if they could be
complementary.
Methods: We performed oral glucose tolerance tests and mean levels of hemoglobin A1c
(HbA1c) measurements on 43 patients referred to a diabetes clinic for possible diabetes. Results
of single and combined use of the FPG and 2hPG criteria were evaluated against the levels of HbA1c
and results re-interpreted in the light of existing reports in the literature.
Results: Our results confirm that the FPG and the 2hPG, being specific and sensitive respectively
for the presence of glucose intolerance or diabetes, are not equivalent. They are shown to be
indeed complementary and a re-definition of diagnostic criteria based on their combined use is
proposed.
Conclusions: We conclude that altering single measurement cut-offs for the diagnosis of diabetes
and altered glucose tolerance will not result in better outcomes. We present the case for a
combined criteria in the diagnosis and definition of diabetes with a FPG≥7 mmol/L AND 2-hour
glucose ≥7.8 mmol/L being used to define diabetes while a FPG<7 mmol/L AND 2-hour glucose
<7.8 mmol/L being used to define normality. Discordant values will define impaired glucose
tolerance (IGT). This proposal requires prospective evaluation in a large cohort.
Introduction
Prior to the National Diabetes Data Group (NDDG) diag-
nostic criteria for diabetes in 1979, there were many dif-
ferent sets of criteria used to diagnose diabetes [1]
resulting in a prevalence of diabetes that differed depend-
ing on the criteria used. In 1979, the NDDG recommend-
ed one set of criteria [2] which was modified by the World
Health Organization (WHO) [3] in 1980. These criteria
were selected based on the results of 3 prospective studies
[4–6] in which subjects without diabetic retinopathy were
given oral glucose tolerance tests and followed for 3 to 8
years, at which time 6% of them had developed this com-
plication [7]. Based on the 2-hour post glucose (2hPG)
values of these individuals, a 2-hour glucose concentra-
tion of ≥ 11.1 mmol/L and a fasting plasma glucose con-
centration of ≥ 7.8 mmol/L were established as the criteria
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betes Association (ADA) convened an expert committee
to revisit these criteria [8]. The committee lowered the
fasting plasma glucose (FPG) concentration for the diag-
nosis of diabetes from ≥ 7.8 mmol/L to ≥ 7.0 mmol/L but
decided to retain the 2-hour value of ≥ 11.1 mmol/L on
the oral glucose tolerance test because a large number of
epidemiological studies in the literature used this value to
define diabetes and changing it "would be very disrup-
tive".
However this 2hPG criterion and the FPG values defined
as diagnostic of diabetes by the World Health Organiza-
tion (WHO) [3] are not equivalent: approximately three
quarters of subjects with diagnostic 2hPG concentrations
(≥ 11.1 mmol/L) have fasting glucose values below the
level defined as diagnostic by the WHO (7.8 mmol/L).[9]
Roughly 75% of subjects who participated in the
NHANES II with diagnostic 2-h values had fasting values
<7.8 mmol/L.[9] Similarly, in relation to the ADA criteria,
there is mounting evidence that there is a sizeable propor-
tion of previously undiagnosed diabetic people with a
2hPG glucose ≥ 11.1 mmol/L but FPG <7.0 mmol/L. This
proportion varies in different populations and ranges
from 32 to 72%.[10–12] It has also been shown, from
pooled analyses of 20 studies conducted in different Euro-
pean countries, that as many as one-third (31%) of those
who are diabetic, according to the 2hPG, have normal
fasting values (<6.1 mmol/1) [12] and therefore, would
not be detected by a screening procedure based essentially
on fasting glucose measurements. In addition, fasting glu-
cose is of little help in diagnosing impaired glucose toler-
ance (IGT) since evidence is accumulating that most
people with IGT (from 54 to 67%) have fasting glucose in
the normal range (<6.1 mmol/L).[12–14]
It seems clear therefore, that not only are these cutoffs not
equivalent in their definition of diabetes but the increased
emphasis given by the expert committee [8] on the fasting
values may not entirely be optimal. One strong argument
for this is that it has been demonstrated that isolated post
load hyperglycemia is a strong predictor of mortality
[10,15,16] and progression to diabetes, [13,14] with pre-
vention of progression to overt diabetes being possible in
this group.[17] Based on the data presented above, the
fasting criteria alone will be unable to detect this interme-
diate group of glucose intolerance. This is not just a con-
sequence of the fasting cutoff, since it has also been
shown, from the pooled data mentioned above [12], that
even if the fasting glucose threshold is lowered to 5.5
mmol/l, (thus detecting 93% of all those with diabetes di-
agnosed on the basis of 2hPG), its ability to identify IGT
(sensitivity) does not improve substantially. It has there-
fore been concluded that the FPG, while being useful to
confirm the overtly diabetic state, misclassifies many peo-
ple with abnormal glucose tolerance as being normal
[18]. Since the latter group can be picked up by the 2hPG
values, and adjustment of the fasting cut-off is of no addi-
tional benefit, it makes sense to use both measurements
together in the in the definition of diabetes. We therefore
evaluated their combined use for this purpose against
mean levels of hemoglobin A1c (HbA1c) in our patient
groups. This was compared with the use of single cut-offs
for either the 2hPG (WHO) or the FPG (ADA) respectively
in the definition of diabetes.
Methods
Study population
The study was a diabetes clinic-based study on glucose in-
tolerance in a small group of resident Kuwaiti and expatri-
ate population in Kuwait. A random sample (n = 43) of
visitors referred from a general clinic with a clinical suspi-
cion of glucose intolerance or diabetes (unexplained con-
stitutional symptoms in an appropriate setting [for
example first degree relatives with diabetes] or symptoms
of diabetes such as polyuria & polyphagia), aged 30 to 70
were included in the study. The OGTT was done by one of
us (AP). Participants who were already treated for diabetes
by insulin, oral anti-diabetic agents, or a physician-pre-
scribed diet were excluded. Only 43 patients were recruit-
ed because we had allocated six months to data collection
from the clinic. Patients are randomly allocated to each of
five clinic physicians by the nursing staff and only new pa-
tients received by AP (n = 43 by six months) were included
in this study.
Glucose, HbA1c and BMI measurements
After 8–10 hours of overnight fasting, blood was collected
for the measurement of FPG. Subsequently, a 75-g oral
glucose (glucose tolerance test beverage, Fisher health-
care, Curtin Matheson Scientific, Houston, Texas, USA)
tolerance test (OGTT) was performed and the plasma glu-
cose level was measured 2 hours later (2hPG). The glucose
levels were determined by means of the oxygen rate meth-
od employing a Beckman Coulter Oxygen Electrode (glu-
cose oxidase method, Beckman Coulter Inc, Galway,
Ireland). HbA1c was measured by the Beckman Synchron
LX system(Beckman Instruments Inc, Fullerton CA,
92834-3100). This utilizes two cartridges, Hb and A1c to
determine A1c concentration as a percentage of total Hb.
The hemoglobin is measured by a colorimetric method
and the A1c concentration by a turbidimetric immunoin-
hibition method. The normal range for the HbA1c in our
lab is 4.3–5.9%. Weight and height were measured with
participants wearing light clothing only, and the body
mass index (BMI) was calculated as weight divided by the
square of the height (kg/m2).Page 2 of 7
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a) Single criteria
Diabetes was diagnosed if the 2hPG was 11.1 mmol/L or
greater, or the FPG was 7.0 mmol/L or greater. Impaired
fasting glucose (IFG) was defined as a FPG between 6.1
mmol/L and 6.9 mmol/L and IGT was diagnosed if the
2hPG was between 7.8 mmol/L and 11 mmol/L.
b) Our combined criteria
For the combined criteria the upper limit for the FPG (spe-
cific test) was combined with the lower limit for the 2hPG
(sensitive test). Normality was based on the 2hPG value
(<7.8 mmol/L) so long as the fasting value was concord-
ant (<7 mmol/L). In the same way, a fasting value was
used to define diabetes (≥ 7 mmol/L) so long as the 2hPG
value was concordant (≥ 7.8 mmol/L). A discordant fast-
ing and 2hPG value defines combined criteria IGT (cIGT).
Statistical methods
All basic statistical analyses were done with Epi-info 6.04d
[19] which was also the database with a cutoff for statisti-
cal significance of 0.05. Graphics were charted on SPSS
Figure 1
Boxplots of HbA1c by various diagnostic criteria. Subdivisions in each of these groups are depicted by different coloured boxes
(red-diabetes, green-impaired, blue-normal). The box encloses the middle 50 percent of patients, and the median is repre-
sented as a horizontal line inside the box. The whiskers are lines that extend from the box to the highest and lowest values
excluding outliers. The left and right plots depict 2-hour and FPG subdivisions respectively while the upper and lower plots
depict comparisons against single and combined criteria clusters respectively (CC = combined criteria). There were two out-
liers (shown in the plots as circles with the patient number) and they were selected based on being more than 1.5 box lengths
from the ends of the box, but were included in the analysis in tables 1 & 2. Diabetes was diagnosed in the same percentage
(63%) of patient's according to either of the single criteria or the combined criteria. One quarter of the diabetics by each single
criterion were not diabetic by the other single criterion.Page 3 of 7
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intervals for the difference in means was calculated using
Statgraphics Plus for Windows version 3.0, Statistical
Graphics Corporation.
Results
The study population consisted of 33 men and 10 women
with a mean age of 46.7 (SD, 9) years. Mean BMI (n = 42,
anthropometric data of one patient was missed at initial
visit) was 28.7 ± 5 kg/M2 (median 29, range 18.3–44.9).
The results of sub-grouping of patients by different diabe-
tes criteria are depicted in the figure and tables 1 & 2.
Discussion
Cutoff points such as those decided on by the ADA or
WHO, allow the comparison of a dichotomy of a test var-
iable against a relevant clinical endpoint. The test result
however should be considered diagnostic of diabetes only
if it separates those at a low and high risk for a clinically
important outcome such as a specific microvascular or
macrovascular complication. For example, the inherent
risk for retinopathy, as demonstrated in epidemiological
studies, was the rationale behind the derivation of the
2hPG of 11.1 mmol/L criterion [20]. As the the HbA1c
level at values ≥ 1% above the upper limit of normal
(ULN) is associated with much greater development of
progression of diabetic retinopathy or microalbuminuria,
[21–24] its value correlates well with microvascular com-
plications and was the standard in this study against
which the various groups were evaluated. It may be point-
ed out here that although the use of the HbA1c in this way
is useful (to define the glycemic status of patient groups
with similar characteristics), it is not suitable for diabetes
screening in individuals and cannot replace plasma glu-
cose. It is true that the level of HbA1c is higher among di-
abetic than among nondiabetic persons, and among
diabetic persons there is a correlation between HbA1c and
various measures of glycemia, but this correlation seen in
groups of patients does not hold for mildly hyperglycemic
patients where the correlation is very poor, probably be-
cause glycemia proceeds at a slow rate and cannot reflect
glycemia in toto [25]. When the HbA1c has been used as
a screening test for individual patients, as expected, it has
an unacceptably low sensitivity [26] that results in very
poor discrimination of normality, IGT and diabetes in in-
dividual patients. It has a good specificity [26], however,
allowing its use for assessment of glycemic control in the
follow-up of diabetics.
Our results first demonstrate that IGT and diabetes by the
2hPG are unable to distinguish different levels of HbA1c
(table 2), suggesting excessive overlap of these two
groups. This is corroborated by other studies where ap-
proximately two thirds of individuals diagnosed as having
diabetes by a 2hPG concentration of 11.1–13.3 mmol/L
on an oral glucose tolerance test have normal HBA1C lev-
els [27]. In addition to such normal HBA1C levels, less
than 5% will have HbA1C levels ≥ 1% above the ULN that
predicts an adverse outcome. Therefore, 95% of these pa-
tients will have met the American Diabetic Association's
goal HbA1c value of less than the upper limit of normal +
1% [28] and will be treated with diet and exercise rather
than pharmacological agents. This is the same treatment
that would be offered to patients with impaired glucose
tolerance, (i.e., those whose 2hPG concentrations on an
oral glucose tolerance test are 7.8–11.0 mmol/L). This is
also corroborated by pooled data in 16 studies presented
by Davidson et al [7] where patients with an HbA1c level
≥ 1% above the ULN have been shown to have a very high
probability of meeting the 2hPG criteria for diabetes
(>95%) while at the same time (as noted above) most of
the subjects with diagnostic 2hPG do not have a HbA1c ≥
1% of the ULN and approximately two-thirds would actu-
ally have a normal HbA1c.[29]
Secondly, we have also demonstrated that the HbA1c in
those with IFG is very distinct from diabetics (by FPG, ta-
ble 2). This is because a lot of the IFG group actually have
normal glucose tolerance, making the separation from di-
abetics even more. This conclusion is supported by a 6
year prospective study of 1342 non-diabetic white Dutch
individuals aged 50–75 years who had an OGTT at base-
line and where IFG was present in only 28% of those with
Table 1: The mean HbA1c (and 95% CI for the difference between 
means) of 2hPG or FPG subgroups within the combined criteria 
groups are reported. There were no significant differences in 
mean HbA1c between subgroups suggesting that the glycemic 
status within combined criteria groups was similar even for differ-
ent FPG or 2hPG levels.
Combined Criteria
Diabetes CIGT
n HbA1c% n HbA1c%
2hPG
Diabetic 20 a8.1 7 b6.9
Impaired 7 a7.6 6 b6.4
FPG
Diabetic 27 7.9
Impaired 0 - 6 c6.3
Normal 7 c7.1
Difference in means (95% CI for difference): a0.4% (-0.56–1.44), b0.5% 
(-0.95–2.03), c-0.8% (-2.2 – 0.6), all non-significantly different from 
zero.Page 4 of 7
(page number not for citation purposes)
BMC Endocrine Disorders 2002, 2 http://www.biomedcentral.com/1472-6823/2/1IGT but was absent in 92% of those without IGT (28%
sensitivity, 92% specificity).[30] Based on the usual prev-
alence of IGT and diabetes in communities, two-thirds of
those with IFG can be expected to have a normal OGTT.
This conclusion is also supported by the data presented by
Davidson et al [31], where only about 13% of individuals
diagnosed to have IFG by virtue of a FPG of 6.1–6.9
mmol/L will have an abnormal HbA1c. Less than 1% will
have HbA1c levels ≥ 1% above the ULN. Therefore 87% of
these persons should require no intervention. These au-
thors (adapted from the table) also reveal that patients
with a normal HbA1c have a very low probability (3%) of
meeting the fasting threshold of 7 mmol/L. (This is in
stark contrast to the people with FPG concentrations of
7.0 or more, two-thirds of whom have abnormal glycated
hemoglobin levels [31])
What are the implications of this? It is clear that the FPG
<7 mmol/L provides no reliable information on whether
an individual is normal or is at risk from future diabetes
or future cardiovascular, eye or kidney disease related to
diabetes.[18] In a similar fashion, the 2hPG provides poor
discrimination of those at future risk from the overtly di-
abetic patients with ongoing risk. This is again confirmed
by the Funagata Diabetes Study in Japan, where the haz-
ard ratios for all cause and cardiovascular mortality were
higher for subjects diagnosed with diabetes according to
the FPG than for subjects diagnosed according to the
2hPG. However subjects with IGT had a higher risk of car-
diovascular mortality than subjects with IFG.[32] These
observations suggest that a diagnostic fasting value repre-
sents a level of glycemia that provides a high level of clin-
ical certainty that the patient does indeed have diabetes,
especially if it is elevated on two occasions [20], whereas
the 2-hour criterion does not. In the same vein, a normal
2hPG provides a high level of clinical certainty that a pa-
tient needs no intervention, whearas the fasting criterion
does not. It then becomes clear that to diagnose normali-
ty, impaired glucose tolerance and diabetes, we need a
combination of these two criteria: One that favours sensi-
tivity to exclude diabetes and the other that favours specif-
icity to diagnose diabetes. The same result can not be
achieved by adjusting cut-offs of single measurements.
We acknowledge that our study is limited by the small
number of participants. It is possible that in table 2, non-
significance with the 2hPG could be related to the small
number of patients. Nevertheless, the analysis in our com-
bined criteria group had the same number of patients and
this was even less in the FPG group but both reached sta-
tistical significance. In table 1, there were even smaller
numbers compared in the cIGT groups, and it is possible
that larger numbers may have attained a significant differ-
ence. This however seems unlikely for the FPG group
where the mean difference was almost 1% higher in the
normal group. We have cited the data in the literature ex-
tensively with our results, and the results from larger stud-
ies are not divergent from our data. Certainly, a larger trial
is warranted to confirm the validity of this diagnostic ap-
proach.
Conclusions
The 2hPG [≥ 7.8 mmol/L] is poorly specific for diabetes
and only its combination with a FPG ≥ 7 mmol/L can be
considered diagnostic of diabetes. In the same vein, a FPG
[< 7 mmol/L] is poorly sensitive for diabetes and only its
combination with a 2hPG < 7.8 can be considered nor-
mality. A discordant result (usually means FPG < 7 mmol/
Table 2: The difference in mean HbA1c and 95% confidence intervals for the difference between the means for the fasting and impaired 
subgroups of all three classification methods are reported. The implications of these differences are discussed in the text.
Glycemic status Difference and 95% CI 
for difference in means
Diabetes IGT/IFG
n HbA1c% n HbA1c%
2hPG 27 7.8 13 7.1 0.7 (-0.15–1.57), p = 0.1
FPG 27 7.9 7 6.2 1.7 (0.79–2.69), p = 0.0007
Combined Criteria 27 7.9 13 6.7 1.2 (0.4 – 2), p = 0.003Page 5 of 7
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should then represent cIGT. Our results also clearly indi-
cate that a combination of both criteria do complement
each other in the definition of diabetes and propose these
criteria (outlined in table 3) for the definition of diabetes,
glucose intolerance or euglycemia. It can be estimated
from the data in the literature that if these combined cri-
teria are applied in a population, three-fourths of those
with IFG will be re-diagnosed as normal by the combined
criteria and 10% of those with normal FPG will be re-di-
agnosed as cIGT by the combined criteria. Assuming a 5%
prevalence of diabetes and 10–11% prevalence of IFG in
the community, equal numbers of patients with either
IFG or normal FPG will switch categories by the combined
criteria. That this switch is appropriate, is indicated by the
similar mean HbA1c of the single cutoff subgroups within
our combined categories in table 1, but will require larger
studies to confirm this. We look forward to the results of
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